Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bupropion plasma levels and CYP2D6 phenotype.

Therapeutic drug monitoring - 1 Oct 1996

Pollock B G, Sweet R A, Kirshner M, Reynolds C F

Abstract excerpt

All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme. To date, nothing in this regard has been published concerning bupropion. We report that plasma level/dose ratios for bupropion, and its metabolites erythrohydrobupropion and threohydrobupropion, were not associated with debrisoquine metabolic status in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2D6
Share to Depressive Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Phenotype

Share to Seizures

Source

Identifiers

PMID: 8885123
DOI: 10.1097/00007691-199610000-00010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bupropion plasma levels and CYP2D6 phenotype.PMID 8885123Read ↗

Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.Semantic proximity Read ↗

Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.Semantic proximity Read ↗

Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.Semantic proximity Read ↗

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.Semantic proximity Read ↗

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Semantic proximity Read ↗

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.Semantic proximity Read ↗

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.Semantic proximity Read ↗

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis.Semantic proximity Read ↗

A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.Semantic proximity Read ↗

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.